Screening and validation of small molecule compounds or agents with known clinical indications that specifically disrupt the interaction of CCNB1IP1 with MYCN as candidate inhibitors can be further explored through preclinical testing and subsequent clinical applications of MYCN‐AM NB. This evidence concerns the gene CCNB1IP1 and neuroblastoma.